This is a randomized, placebo-controlled, cross-over study with 4 arms. Healthy and GH
deficient adults ages 18-45 years will be studied. Arms will consist of 21-day treatment
periods and be separated by 8-week washout periods. Subjects will receive, in random order:
i) GH alone, ii) GH with liraglutide, iii) liraglutide alone and iv) placebo. Each phase of
the study will consist of a 7-day baseline period including 2 days of testing and 21 days on
therapy with visits on days 2, 7, 14 and 21. Testing before, during and at the completion of
each arm will include blood sampling and assessments of insulin resistance, energy
expenditure and body composition.